Status:
COMPLETED
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin
Lead Sponsor:
University of Catania
Conditions:
Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis
Fatigue in Workers With Chronic C Hepatitis
Eligibility:
All Genders
45-65 years
Phase:
PHASE4
Brief Summary
To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.
Eligibility Criteria
Inclusion
- workers who were 18 years of age or older
- Workers who were infected by HCV and had a quantifiable serum HCV RNA level (as determined by polimerase chain reaction, COBAS AmpliPrep/COBAS TaqMan - ROCHE)
- Cirrhotic workers with a Child-Pugh score less than 7
Exclusion
- workers who had other liver diseases
- cancer
- severe jaundice
- pulmonary and renal chronic diseases,
- prostatic diseases
- autoimmune diseases
- diabetes mellitus
- decompensated cirrhosis
- pregnancy
- cardiopathy
- hemoglobinopathies
- hemocromatosis
- major depression
- severe psychiatric pathological conditions
Key Trial Info
Start Date :
October 1 1997
Trial Type :
INTERVENTIONAL
End Date :
October 1 1997
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01913964
Start Date
October 1 1997
End Date
October 1 1997
Last Update
August 1 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.